Organovo Holdings renames to VivoSim Labs, emerges from stealth to target FDA animal testing phase-out

VivoSim Labs, INC.

Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.
In conjunction with the name change, VivoSim issued a press release announcing emergence from stealth mode to provide NAM models for liver and intestinal toxicology.
The FDA announced on April 10, 2025 a plan to phase out animal testing requirements, representing a potential >$10B market opportunity for VivoSim's non-animal technologies.
VivoSim’s NAMkind liver model achieved industry-best correlation with known clinical failures, aiming to reduce clinical trial failures and cut drug development costs by 50%.
The company's NAMkind intestine models offer novel readouts for drug candidate selection, targeting reduction of patient side effects from chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.